Hyaluronic acid (intraarticular): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Hyaluronic acid (intraarticular)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=
|authorTag={{AV}}<!--Overview-->
{{AV}}
|aOrAn=a
 
<!--Overview-->
 
|genericName=
 
 
 
|aOrAn=
 
a
 
|drugClass=[[cartilaginous defect repair agent]]
|drugClass=[[cartilaginous defect repair agent]]
 
|indicationType=treatment
 
|indication=[[osteoarthritis]] of knee
|indication=[[Osteoarthritis]] of knee
|adverseReactions=injection site [[pain]], [[injection site reaction]], [[arthralgia]]  
 
 
 
|hasBlackBoxWarning=
 
 
|adverseReactions=Injection site [[pain]], [[injection site reaction]], [[arthralgia]]  




<!--Black Box Warning-->
<!--Black Box Warning-->
 
|blackBoxWarningTitle=Title
|blackBoxWarningTitle=
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
* Content
Line 39: Line 17:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=For the treatment of [[Osteoarthritis]] of knee
|fdaLIADAdult=
For the treatment of [[Osteoarthritis]] of knee




Line 47: Line 23:


<!--Guideline-Supported Use (Adult)-->
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
|fdaLIADPed=
 
 
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedNoGuideSupport=
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
 
|contraindications=<!--Warnings-->
|contraindications=
|warnings=<!--Adverse Reactions-->
 
 
<!--Warnings-->
 
|warnings=
 
 
<!--Adverse Reactions-->


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
 
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.




<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
 
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.




<!--Drug Interactions-->
<!--Drug Interactions-->
 
|drugInteractions=<!--Use in Specific Populations-->
|drugInteractions=
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
<!--Use in Specific Populations-->
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInPregnancyFDA=
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInPregnancyAUS=
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[renal impairment]].
 
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[hepatic impairment]].
 
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are [[immunocompromised]].
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with [[renal impairment]].
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with [[hepatic impairment]].
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are [[immunocompromised]].


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
 
|administration=* Intraarticular
|administration=
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Intraarticular
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.




<!--IV Compatibility-->
<!--IV Compatibility-->
 
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
<!--Overdosage-->
 
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
|overdose=
 
 
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->


<!--Drug box 2-->
<!--Drug box 2-->
|drugBox={{Chembox2
|drugBox={{Chembox2


Line 259: Line 152:


<!--Mechanism of Action-->
<!--Mechanism of Action-->
 
|mechAction=<!--Structure-->
|mechAction=
|structure=<!--Pharmacodynamics-->
 
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Structure-->
 
|structure=
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


<!--Pharmacokinetics-->
<!--Pharmacokinetics-->
 
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.


<!--Nonclinical Toxicology-->
<!--Nonclinical Toxicology-->
 
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


<!--Clinical Studies-->
<!--Clinical Studies-->
 
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


<!--How Supplied-->
<!--How Supplied-->
 
|howSupplied=*3mL in a 10mL Single Use Syringe.
|howSupplied=
*Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing.
*3mL in a 10mL Single Use Syringe.
* Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing.


<!--Patient Counseling Information-->
<!--Patient Counseling Information-->
 
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


<!--Precautions with Alcohol-->
<!--Precautions with Alcohol-->
 
|alcohol=<!--Brand Names-->
|alcohol=
|brandNames=<!--Look-Alike Drug Names-->
 
|lookAlike=<!--Drug Shortage Status-->
 
 
<!--Brand Names-->
 
|brandNames=
 
 
 
<!--Look-Alike Drug Names-->
 
|lookAlike=
 
 
<!--Drug Shortage Status-->
 
|drugShortage=
|drugShortage=
}}
}}
<!--Pill Image-->
<!--Pill Image-->


Latest revision as of 16:28, 20 August 2015

Hyaluronic acid (intraarticular)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Hyaluronic acid (intraarticular) is a cartilaginous defect repair agent that is FDA approved for the treatment of osteoarthritis of knee. Common adverse reactions include injection site pain, injection site reaction, arthralgia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

For the treatment of Osteoarthritis of knee

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (intraarticular) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (intraarticular) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Hyaluronic acid (intraarticular) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (intraarticular) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (intraarticular) in pediatric patients.

Contraindications

There is limited information regarding Hyaluronic acid (intraarticular) Contraindications in the drug label.

Warnings

There is limited information regarding Hyaluronic acid (intraarticular) Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Hyaluronic acid (intraarticular) in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Hyaluronic acid (intraarticular) in the drug label.

Drug Interactions

There is limited information regarding Hyaluronic acid (intraarticular) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Hyaluronic acid (intraarticular) in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hyaluronic acid (intraarticular) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Hyaluronic acid (intraarticular) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Hyaluronic acid (intraarticular) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Hyaluronic acid (intraarticular) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Intraarticular

Monitoring

There is limited information regarding Monitoring of Hyaluronic acid (intraarticular) in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Hyaluronic acid (intraarticular) in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Hyaluronic acid (intraarticular) in the drug label.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox SolubilityInWaterTemplate:Chembox SPhrasesTemplate:Chembox Lethal amounts (set)Template:Chembox Supplement
Template:Chembox header2 | Hyaluronic acid (intraarticular)
Identifiers
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
UNII
Properties
(C14H21NO11)n
Hazards
Related compounds
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Hyaluronic acid (intraarticular) Mechanism of Action in the drug label.

Structure

There is limited information regarding Hyaluronic acid (intraarticular) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Hyaluronic acid (intraarticular) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Hyaluronic acid (intraarticular) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Hyaluronic acid (intraarticular) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Hyaluronic acid (intraarticular) in the drug label.

How Supplied

  • 3mL in a 10mL Single Use Syringe.
  • Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing.

Storage

There is limited information regarding Hyaluronic acid (intraarticular) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Hyaluronic acid (intraarticular) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Hyaluronic acid (intraarticular) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Hyaluronic acid (intraarticular) in the drug label.

Precautions with Alcohol

Alcohol-Hyaluronic acid (intraarticular) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Hyaluronic acid (intraarticular) Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Hyaluronic acid (intraarticular) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Template:ChemID, consulté le 12 février 2009



{{#subobject: 

 |Label Page=Hyaluronic acid (intraarticular)
 |Label Name=Hyaluronic acid (intraarticular)03.png

}}


{{#subobject: 

 |Label Page=Hyaluronic acid (intraarticular)
 |Label Name=Hyaluronic acid (intraarticular)04.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Hyaluronic_acid_(intraarticular)&oldid=1136780"